{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:42:09Z","timestamp":1784238129430,"version":"3.55.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart failure treatment depends on several drugs, all providing improvement in outcome, but that cannot be realistically used all together in the same patient. It would be useful to have a tool that allows the arrangement of the most appropriate therapy cocktail for each patient. The aim of this article is to show the main differences in the effects of several drugs on cardiopulmonary function in patients with heart failure, both while resting and during exercise, and to discuss how these differences can be taken into account when choosing the most appropriate therapeutic protocol. In summary, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers act synergistically to increase exercise capacity and peak oxygen uptake, but through different mechanisms: the former improving lung diffusion and exercise ventilatory efficiency, an action that is counteracted by concomitant aspirin therapy, and the latter probably by improving muscle perfusion. As for \u03b2-blockers, nonselective compounds, such as carvedilol, improve ventilation efficiency on the one hand, but interfere with lung diffusion on the other, and they are probably less tolerated under hypoxic conditions. On the contrary, \u03b21-selective compounds, such as bisoprolol or nebivolol, have a neutral effect on both lung diffusion and ventilation efficiency. These observations could be the basis for the choice of pharmacological therapy in patients with heart failure.<\/jats:p>","DOI":"10.1513\/annalsats.201611-887fr","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T16:24:23Z","timestamp":1491323063000},"page":"S67-S73","source":"Crossref","is-referenced-by-count":9,"title":["Cardiopulmonary Exercise Test as a Tool to Choose Therapy in Heart Failure"],"prefix":"10.1093","volume":"14","author":[{"given":"Mauro","family":"Contini","sequence":"first","affiliation":[{"name":"Centro Cardiologico Monzino, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"key":"2026020403044678700_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"2026020403044678700_bib2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"2026020403044678700_bib3","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"2026020403044678700_bib4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2026020403044678700_bib5","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"MERIT-HF Study Group","year":"1999","journal-title":"Lancet"},{"key":"2026020403044678700_bib6","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026020403044678700_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","journal-title":"Lancet"},{"key":"2026020403044678700_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2026020403044678700_bib9","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2026020403044678700_bib10","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2026020403044678700_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026020403044678700_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026020403044678700_bib13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026020403044678700_bib14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026020403044678700_bib15","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/oxfordjournals.eurheartj.a061019","article-title":"The lungs in chronic heart failure","volume":"16","author":"Chua","year":"1995","journal-title":"Eur Heart J"},{"key":"2026020403044678700_bib16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1378\/chest.98.4.816","article-title":"Ventilatory and diffusion abnormalities in potential heart transplant recipients","volume":"98","author":"Wright","year":"1990","journal-title":"Chest"},{"key":"2026020403044678700_bib17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ahj.2010.03.034","article-title":"Effects of beta-blockers on ventilation efficiency in heart failure","volume":"159","author":"Agostoni","year":"2010","journal-title":"Am Heart J"},{"key":"2026020403044678700_bib18","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1161\/01.CIR.96.7.2221","article-title":"Lung function and exercise gas exchange in chronic heart failure","volume":"96","author":"Wasserman","year":"1997","journal-title":"Circulation"},{"key":"2026020403044678700_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/hrt.72.2.140","article-title":"Increased alveolar\/capillary membrane resistance to gas transfer in patients with chronic heart failure","volume":"72","author":"Puri","year":"1994","journal-title":"Br Heart J"},{"key":"2026020403044678700_bib20","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1093\/eurheartj\/ehl302","article-title":"Gas diffusion and alveolar\u2013capillary unit in chronic heart failure","volume":"27","author":"Agostoni","year":"2006","journal-title":"Eur Heart J"},{"key":"2026020403044678700_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1053\/euhj.2001.2803","article-title":"Alveolar\u2013capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure","volume":"23","author":"Guazzi","year":"2002","journal-title":"Eur Heart J"},{"key":"2026020403044678700_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/euhj.1999.1863","article-title":"Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE\/VCO2 slope and peak VO2","volume":"21","author":"Francis","year":"2000","journal-title":"Eur Heart J"},{"key":"2026020403044678700_bib23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/01.CIR.95.7.1930","article-title":"Improvement of alveolar\u2013capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin","volume":"95","author":"Guazzi","year":"1997","journal-title":"Circulation"},{"key":"2026020403044678700_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/cs0960017","article-title":"Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane","volume":"96","author":"Guazzi","year":"1999","journal-title":"Clin Sci (Lond)"},{"key":"2026020403044678700_bib25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0002-8703(99)70109-2","article-title":"Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors","volume":"138","author":"Guazzi","year":"1999","journal-title":"Am Heart J"},{"key":"2026020403044678700_bib26","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/archinte.163.13.1574","article-title":"Aspirin\u2013angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin","volume":"163","author":"Guazzi","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026020403044678700_bib27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0009-9236(99)70111-6","article-title":"Angiotensin-converting enzyme inhibition facilitates alveolar\u2013capillary gas transfer and improves ventilation\u2013perfusion coupling in patients with left ventricular dysfunction","volume":"65","author":"Guazzi","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"2026020403044678700_bib28","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0002-9149(97)00781-9","article-title":"Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy","volume":"80","author":"Guazzi","year":"1997","journal-title":"Am J Cardiol"},{"key":"2026020403044678700_bib29","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0002-9149(99)00495-6","article-title":"Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure","volume":"84","author":"Guazzi","year":"1999","journal-title":"Am J Cardiol"},{"key":"2026020403044678700_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10557-016-6645-6","article-title":"ACE-inhibition benefit on lung function in heart failure is modulated by ACE insertion\/deletion polymorphism","volume":"30","author":"Contini","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026020403044678700_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"2026020403044678700_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(97)80008-6","article-title":"Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease","volume":"349","author":"Australia\/New Zealand Heart Failure Research Collaborative Group","year":"1997","journal-title":"Lancet"},{"key":"2026020403044678700_bib33","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/0735-1097(94)90174-0","article-title":"Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy","volume":"24","author":"Metra","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"2026020403044678700_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1755-5922.2010.00184.x","article-title":"Chronotropic incompetence and functional capacity in chronic heart failure: no role of \u03b2-blockers and \u03b2-blocker dose","volume":"30","author":"Magr\u00ec","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"2026020403044678700_bib35","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1378\/chest.122.6.2062","article-title":"Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients","volume":"122","author":"Agostoni","year":"2002","journal-title":"Chest"},{"key":"2026020403044678700_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cardfail.2004.11.008","article-title":"Effects of beta-blocker therapy on ventilatory responses to exercise in patients with heart failure","volume":"11","author":"Wolk","year":"2005","journal-title":"J Card Fail"},{"key":"2026020403044678700_bib37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ejheart.2004.05.006","article-title":"The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure","volume":"7","author":"Witte","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2026020403044678700_bib38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejheart.2006.02.001","article-title":"Carvedilol reduces exercise-induced hyperventilation: a benefit in normoxia and a problem with hypoxia","volume":"8","author":"Agostoni","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026020403044678700_bib39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ejheart.2007.04.006","article-title":"Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?","volume":"9","author":"Agostoni","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026020403044678700_bib40","doi-asserted-by":"crossref","first-page":"e61877","DOI":"10.1371\/journal.pone.0061877","article-title":"Role of alveolar \u03b22-adrenergic receptors on lung fluid clearance and exercise ventilation in healthy humans","volume":"8","author":"Paolillo","year":"2013","journal-title":"PLoS One"},{"key":"2026020403044678700_bib41","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ijcard.2013.01.277","article-title":"Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial","volume":"168","author":"Contini","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026020403044678700_bib42","doi-asserted-by":"crossref","first-page":"L685","DOI":"10.1152\/ajplung.00247.2005","article-title":"Mechanisms of pulmonary edema clearance","volume":"289","author":"Mutlu","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026020403044678700_bib43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCHEARTFAILURE.111.965186","article-title":"Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training","volume":"5","author":"Swank","year":"2012","journal-title":"Circ Heart Fail"},{"key":"2026020403044678700_bib44","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC)","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/14\/Supplement_1\/S67\/66716220\/annalsats_14_supplement_1_s67.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/14\/Supplement_1\/S67\/66716220\/annalsats_14_supplement_1_s67.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:05:06Z","timestamp":1770192306000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/14\/Supplement_1\/S67\/8454197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":44,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2017,7,1]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201611-887fr","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,7,1]]}}}